Lymphoma
Conditions
Interventions
1:Test product: NK cells derived from autologous peripheral blood
reinfusion dose: according to patient weight: 2×108/kg
reinfusion route: intravenous infusion/bolus injection for 30 minutes. Reinfusion program: infusion every 3 months, four consecutive infusions
Sponsors
Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients or their legal guardians voluntarily participate and sign the informed consent; 2. Male or female patients aged 18 to 70 years (including 18 and 70 years old); 3. Diagnosed as lymphoma by pathological and histological examination; 4. Subject: After pre-treatment, patients with lymphoma who achieved treatment response (complete remission/partial remission) were evaluated at the final stage. 5. The patient's main tissues and organs function well: 1) Liver function: ALT/AST= 95%; 4) Heart function: Left ventricular ejection fraction (LVEF)>=40%. 6. The patient did not receive any chemotherapy, radiotherapy, immunotherapy (such as immunosuppressive drugs) and other anti-cancer treatments within 4 weeks before enrollment, and his previous treatment-related toxic reactions have recovered to = 3 months.
Exclusion criteria
Exclusion criteria: 1. Women who are pregnant (positive urine/blood pregnancy test) or breastfeeding; 2. Men or women who have a conception plan within the past year; 3. The patient cannot guarantee effective contraception (condom or contraceptive, etc.) within 1 year after enrollment; 4. The patient has an uncontrollable infection within 4 weeks before enrollment; 5. Active hepatitis B/C virus; 6. HIV infected patients; 7. Suffering from severe autoimmune disease or immunodeficiency disease; 8. The patient is allergic and is allergic to antibodies or cytokines and other large molecular biological drugs; 9. The patient participated in other clinical trials within 6 weeks before enrollment; 10. Systemic use of hormones (except for patients using inhaled hormones) within 4 weeks before enrollment; 11. Suffering from mental illness; According to the investigator's judgment, the patient has other situations that are not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events related to NK cell therapy;Serious adverse event;Abnormal laboratory examination with clinical significance; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactWei Sang
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed